Cytokinetics, Incorporated
General ticker "CYTK" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $5.2B (TTM average)
Cytokinetics, Incorporated follows the US Stock Market performance with the rate: 40.3%.
Estimated limits based on current volatility of 2.4%: low 63.59$, high 66.67$
Factors to consider:
- Total employees count: 498 (+17.7%) as of 2024
- Top business risk factors: Regulatory and compliance, Insufficient funding, Liquidity and credit risks, Restrictive covenants, Labor/talent shortage/retention
- Current price 10.2% above estimated high
- Earnings for 9 months up through Q3 are below our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2024-12-31 to 2026-12-31
- 2024-12-31 to 2025-12-31 estimated range: [25.18$, 60.39$]
- 2025-12-31 to 2026-12-31 estimated range: [17.69$, 44.28$]
Financial Metrics affecting the CYTK estimates:
- Negative: with PPE of -9.1 at the end of fiscal year the price was very high
- Negative: negative Operating income
- Negative: Operating cash flow per share per price, % of -7.41 <= 0.33
- Negative: negative Industry operating cash flow (median)
- Negative: negative Net income
- Negative: Shareholder equity ratio, % of -9.66 <= 18.93
- Positive: -14.38 < Investing cash flow per share per price, % of -10.35
Short-term CYTK quotes
Long-term CYTK plot with estimates
Financial data
| YTD | 2022-12-31 | 2023-12-31 | 2024-12-31 |
|---|---|---|---|
| Operating Revenue | $94.59MM | $7.53MM | $18.47MM |
| Operating Expenses | $418.79MM | $503.74MM | $554.72MM |
| Operating Income | $-324.20MM | $-496.20MM | $-536.25MM |
| Non-Operating Income | $-76.09MM | $-30.04MM | $-53.28MM |
| Interest Expense | $19.41MM | $57.67MM | $86.51MM |
| R&D Expense | $240.81MM | $330.12MM | $339.41MM |
| Income(Loss) | $-400.30MM | $-526.24MM | $-589.53MM |
| Profit(Loss)* | $-388.95MM | $-526.24MM | $-589.53MM |
| Stockholders Equity | $-107.90MM | $-386.32MM | $-135.37MM |
| Assets | $1,014.77MM | $824.32MM | $1,401.67MM |
| Operating Cash Flow | $-299.52MM | $-414.33MM | $-395.89MM |
| Capital expenditure | $11.34MM | $1.42MM | $3.91MM |
| Investing Cash Flow | $-262.13MM | $239.25MM | $-553.10MM |
| Financing Cash Flow | $516.17MM | $221.32MM | $930.61MM |
| Earnings Per Share** | $-4.33 | $-5.45 | $-5.26 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.